Intravitreal pegaptanib sodium (Macugen®) for diabetic macular oedema
. Purpose: To report the functional and anatomical outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen®) in patients with diabetic macular oedema (DMO). Methods: We conducted a retrospective outcome analysis, by optical coherence tomography (OCT) and best‐corrected visual ac...
Gespeichert in:
| Veröffentlicht in: | Acta ophthalmologica (Oxford, England) England), 2009-09, Vol.87 (6), p.623-630 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 630 |
|---|---|
| container_issue | 6 |
| container_start_page | 623 |
| container_title | Acta ophthalmologica (Oxford, England) |
| container_volume | 87 |
| creator | Querques, Giuseppe Bux, Anna V. Martinelli, Domenico Iaculli, Cristiana Noci, Nicola D. |
| description | .
Purpose: To report the functional and anatomical outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen®) in patients with diabetic macular oedema (DMO).
Methods: We conducted a retrospective outcome analysis, by optical coherence tomography (OCT) and best‐corrected visual acuity (BCVA), of eyes with DMO treated with intravitreal pegaptanib sodium. Moreover, we evaluated the foveal transverse photoreceptor (PR) band integrity in the OCT images at the time of the last follow‐up visit.
Results: Sixty‐three eyes of 48 patients with a minimum of 6 months of follow‐up were included for analysis. Intravitreal pegaptanib was found to produce significant improvements in mean BCVA (p = 0.019) and reductions in mean central macular thickness (CMT) (p |
| doi_str_mv | 10.1111/j.1755-3768.2009.01580.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67631029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67631029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4830-7a3e37106c1e2f21d1b00c7ce28a1606090b3a688d4485afe6d49575a9f794e83</originalsourceid><addsrcrecordid>eNqNkE1OwzAQhS0EoqVwBZQVgkXCOD-2s2BRVRQqFXUBSOwsJ5lUrvJT7ATaS3EITkZCq7JlNjOaee-N9BHiUPBoV7crj_IocgPOhOcDxB7QSIC3OSLDw-H4MEdvA3Jm7QqAUcbCUzKgMeNCUBiS6axqjPrQjUFVOGtcqnWjKp04ts50WzrXTyptl1h9f904eW2cTKsEG506ZbcvlHFqzLBU5-QkV4XFi30fkdfp_cvk0Z0vHmaT8dxNQxGAy1WAAafAUop-7tOMJgApT9EXijJgEEMSKCZEFoYiUjmyLIwjHqk453GIIhiRq13u2tTvLdpGltqmWBSqwrq1knEWUPDjTih2wtTU1hrM5droUpmtpCB7hnIlezyyRyV7hvKXodx01sv9jzYpMfsz7qF1grud4FMXuP13sBwvnvsp-AH_Un_Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67631029</pqid></control><display><type>article</type><title>Intravitreal pegaptanib sodium (Macugen®) for diabetic macular oedema</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Querques, Giuseppe ; Bux, Anna V. ; Martinelli, Domenico ; Iaculli, Cristiana ; Noci, Nicola D.</creator><creatorcontrib>Querques, Giuseppe ; Bux, Anna V. ; Martinelli, Domenico ; Iaculli, Cristiana ; Noci, Nicola D.</creatorcontrib><description>.
Purpose: To report the functional and anatomical outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen®) in patients with diabetic macular oedema (DMO).
Methods: We conducted a retrospective outcome analysis, by optical coherence tomography (OCT) and best‐corrected visual acuity (BCVA), of eyes with DMO treated with intravitreal pegaptanib sodium. Moreover, we evaluated the foveal transverse photoreceptor (PR) band integrity in the OCT images at the time of the last follow‐up visit.
Results: Sixty‐three eyes of 48 patients with a minimum of 6 months of follow‐up were included for analysis. Intravitreal pegaptanib was found to produce significant improvements in mean BCVA (p = 0.019) and reductions in mean central macular thickness (CMT) (p < 0.001) as soon as the 6‐week follow‐up. Most eyes (60/63) required a mean of 3.03 ± 0.9 repeated treatments, over a mean follow‐up period of 6.7 ± 1.2 months, to achieve significant improvements in mean BCVA (p < 0.001) and mean CMT (p < 0.001). In our series, the lower visual acuities tended to congregate in the group with the less‐defined PR band (p < 0.001) and the lower CMT tended to congregate in the group with the best‐defined PR band (p = 0.04), even though the higher CMT did not tend to congregate in the group with the less‐defined PR band.
Conclusion: Our findings demonstrate that selective inhibition by intravitreal pegaptanib sodium of vascular endothelial growth factor (VEGF)‐165 may produce a clinically meaningful and statistically significant benefit in the treatment of DMO.</description><identifier>ISSN: 1755-375X</identifier><identifier>EISSN: 1755-3768</identifier><identifier>DOI: 10.1111/j.1755-3768.2009.01580.x</identifier><identifier>PMID: 19678810</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Aged, 80 and over ; Aptamers, Nucleotide - administration & dosage ; diabetic macular oedema ; Diabetic Retinopathy - diagnosis ; Diabetic Retinopathy - drug therapy ; Diabetic Retinopathy - physiopathology ; Eyeglasses ; Female ; Follow-Up Studies ; Fovea Centralis - pathology ; Humans ; Injections ; laser photocoagulation ; Macugen ; Macula Lutea - drug effects ; Macula Lutea - pathology ; Macular Edema - diagnosis ; Macular Edema - drug therapy ; Macular Edema - physiopathology ; Male ; Middle Aged ; optical coherence tomography ; pegaptanib sodium ; Photoreceptor Cells, Vertebrate - pathology ; Retrospective Studies ; Tomography, Optical Coherence - methods ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity - drug effects ; Vitreous Body</subject><ispartof>Acta ophthalmologica (Oxford, England), 2009-09, Vol.87 (6), p.623-630</ispartof><rights>2009 The Authors. Journal compilation © 2009 Acta Ophthalmol</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4830-7a3e37106c1e2f21d1b00c7ce28a1606090b3a688d4485afe6d49575a9f794e83</citedby><cites>FETCH-LOGICAL-c4830-7a3e37106c1e2f21d1b00c7ce28a1606090b3a688d4485afe6d49575a9f794e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1755-3768.2009.01580.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1755-3768.2009.01580.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19678810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Querques, Giuseppe</creatorcontrib><creatorcontrib>Bux, Anna V.</creatorcontrib><creatorcontrib>Martinelli, Domenico</creatorcontrib><creatorcontrib>Iaculli, Cristiana</creatorcontrib><creatorcontrib>Noci, Nicola D.</creatorcontrib><title>Intravitreal pegaptanib sodium (Macugen®) for diabetic macular oedema</title><title>Acta ophthalmologica (Oxford, England)</title><addtitle>Acta Ophthalmol</addtitle><description>.
Purpose: To report the functional and anatomical outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen®) in patients with diabetic macular oedema (DMO).
Methods: We conducted a retrospective outcome analysis, by optical coherence tomography (OCT) and best‐corrected visual acuity (BCVA), of eyes with DMO treated with intravitreal pegaptanib sodium. Moreover, we evaluated the foveal transverse photoreceptor (PR) band integrity in the OCT images at the time of the last follow‐up visit.
Results: Sixty‐three eyes of 48 patients with a minimum of 6 months of follow‐up were included for analysis. Intravitreal pegaptanib was found to produce significant improvements in mean BCVA (p = 0.019) and reductions in mean central macular thickness (CMT) (p < 0.001) as soon as the 6‐week follow‐up. Most eyes (60/63) required a mean of 3.03 ± 0.9 repeated treatments, over a mean follow‐up period of 6.7 ± 1.2 months, to achieve significant improvements in mean BCVA (p < 0.001) and mean CMT (p < 0.001). In our series, the lower visual acuities tended to congregate in the group with the less‐defined PR band (p < 0.001) and the lower CMT tended to congregate in the group with the best‐defined PR band (p = 0.04), even though the higher CMT did not tend to congregate in the group with the less‐defined PR band.
Conclusion: Our findings demonstrate that selective inhibition by intravitreal pegaptanib sodium of vascular endothelial growth factor (VEGF)‐165 may produce a clinically meaningful and statistically significant benefit in the treatment of DMO.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aptamers, Nucleotide - administration & dosage</subject><subject>diabetic macular oedema</subject><subject>Diabetic Retinopathy - diagnosis</subject><subject>Diabetic Retinopathy - drug therapy</subject><subject>Diabetic Retinopathy - physiopathology</subject><subject>Eyeglasses</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fovea Centralis - pathology</subject><subject>Humans</subject><subject>Injections</subject><subject>laser photocoagulation</subject><subject>Macugen</subject><subject>Macula Lutea - drug effects</subject><subject>Macula Lutea - pathology</subject><subject>Macular Edema - diagnosis</subject><subject>Macular Edema - drug therapy</subject><subject>Macular Edema - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>optical coherence tomography</subject><subject>pegaptanib sodium</subject><subject>Photoreceptor Cells, Vertebrate - pathology</subject><subject>Retrospective Studies</subject><subject>Tomography, Optical Coherence - methods</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Visual Acuity - drug effects</subject><subject>Vitreous Body</subject><issn>1755-375X</issn><issn>1755-3768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1OwzAQhS0EoqVwBZQVgkXCOD-2s2BRVRQqFXUBSOwsJ5lUrvJT7ATaS3EITkZCq7JlNjOaee-N9BHiUPBoV7crj_IocgPOhOcDxB7QSIC3OSLDw-H4MEdvA3Jm7QqAUcbCUzKgMeNCUBiS6axqjPrQjUFVOGtcqnWjKp04ts50WzrXTyptl1h9f904eW2cTKsEG506ZbcvlHFqzLBU5-QkV4XFi30fkdfp_cvk0Z0vHmaT8dxNQxGAy1WAAafAUop-7tOMJgApT9EXijJgEEMSKCZEFoYiUjmyLIwjHqk453GIIhiRq13u2tTvLdpGltqmWBSqwrq1knEWUPDjTih2wtTU1hrM5droUpmtpCB7hnIlezyyRyV7hvKXodx01sv9jzYpMfsz7qF1grud4FMXuP13sBwvnvsp-AH_Un_Y</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Querques, Giuseppe</creator><creator>Bux, Anna V.</creator><creator>Martinelli, Domenico</creator><creator>Iaculli, Cristiana</creator><creator>Noci, Nicola D.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200909</creationdate><title>Intravitreal pegaptanib sodium (Macugen®) for diabetic macular oedema</title><author>Querques, Giuseppe ; Bux, Anna V. ; Martinelli, Domenico ; Iaculli, Cristiana ; Noci, Nicola D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4830-7a3e37106c1e2f21d1b00c7ce28a1606090b3a688d4485afe6d49575a9f794e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aptamers, Nucleotide - administration & dosage</topic><topic>diabetic macular oedema</topic><topic>Diabetic Retinopathy - diagnosis</topic><topic>Diabetic Retinopathy - drug therapy</topic><topic>Diabetic Retinopathy - physiopathology</topic><topic>Eyeglasses</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fovea Centralis - pathology</topic><topic>Humans</topic><topic>Injections</topic><topic>laser photocoagulation</topic><topic>Macugen</topic><topic>Macula Lutea - drug effects</topic><topic>Macula Lutea - pathology</topic><topic>Macular Edema - diagnosis</topic><topic>Macular Edema - drug therapy</topic><topic>Macular Edema - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>optical coherence tomography</topic><topic>pegaptanib sodium</topic><topic>Photoreceptor Cells, Vertebrate - pathology</topic><topic>Retrospective Studies</topic><topic>Tomography, Optical Coherence - methods</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Visual Acuity - drug effects</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Querques, Giuseppe</creatorcontrib><creatorcontrib>Bux, Anna V.</creatorcontrib><creatorcontrib>Martinelli, Domenico</creatorcontrib><creatorcontrib>Iaculli, Cristiana</creatorcontrib><creatorcontrib>Noci, Nicola D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta ophthalmologica (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Querques, Giuseppe</au><au>Bux, Anna V.</au><au>Martinelli, Domenico</au><au>Iaculli, Cristiana</au><au>Noci, Nicola D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravitreal pegaptanib sodium (Macugen®) for diabetic macular oedema</atitle><jtitle>Acta ophthalmologica (Oxford, England)</jtitle><addtitle>Acta Ophthalmol</addtitle><date>2009-09</date><risdate>2009</risdate><volume>87</volume><issue>6</issue><spage>623</spage><epage>630</epage><pages>623-630</pages><issn>1755-375X</issn><eissn>1755-3768</eissn><abstract>.
Purpose: To report the functional and anatomical outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen®) in patients with diabetic macular oedema (DMO).
Methods: We conducted a retrospective outcome analysis, by optical coherence tomography (OCT) and best‐corrected visual acuity (BCVA), of eyes with DMO treated with intravitreal pegaptanib sodium. Moreover, we evaluated the foveal transverse photoreceptor (PR) band integrity in the OCT images at the time of the last follow‐up visit.
Results: Sixty‐three eyes of 48 patients with a minimum of 6 months of follow‐up were included for analysis. Intravitreal pegaptanib was found to produce significant improvements in mean BCVA (p = 0.019) and reductions in mean central macular thickness (CMT) (p < 0.001) as soon as the 6‐week follow‐up. Most eyes (60/63) required a mean of 3.03 ± 0.9 repeated treatments, over a mean follow‐up period of 6.7 ± 1.2 months, to achieve significant improvements in mean BCVA (p < 0.001) and mean CMT (p < 0.001). In our series, the lower visual acuities tended to congregate in the group with the less‐defined PR band (p < 0.001) and the lower CMT tended to congregate in the group with the best‐defined PR band (p = 0.04), even though the higher CMT did not tend to congregate in the group with the less‐defined PR band.
Conclusion: Our findings demonstrate that selective inhibition by intravitreal pegaptanib sodium of vascular endothelial growth factor (VEGF)‐165 may produce a clinically meaningful and statistically significant benefit in the treatment of DMO.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19678810</pmid><doi>10.1111/j.1755-3768.2009.01580.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1755-375X |
| ispartof | Acta ophthalmologica (Oxford, England), 2009-09, Vol.87 (6), p.623-630 |
| issn | 1755-375X 1755-3768 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67631029 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Aged, 80 and over Aptamers, Nucleotide - administration & dosage diabetic macular oedema Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Diabetic Retinopathy - physiopathology Eyeglasses Female Follow-Up Studies Fovea Centralis - pathology Humans Injections laser photocoagulation Macugen Macula Lutea - drug effects Macula Lutea - pathology Macular Edema - diagnosis Macular Edema - drug therapy Macular Edema - physiopathology Male Middle Aged optical coherence tomography pegaptanib sodium Photoreceptor Cells, Vertebrate - pathology Retrospective Studies Tomography, Optical Coherence - methods Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects Vitreous Body |
| title | Intravitreal pegaptanib sodium (Macugen®) for diabetic macular oedema |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A48%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravitreal%20pegaptanib%20sodium%20(Macugen%C2%AE)%20for%20diabetic%20macular%20oedema&rft.jtitle=Acta%20ophthalmologica%20(Oxford,%20England)&rft.au=Querques,%20Giuseppe&rft.date=2009-09&rft.volume=87&rft.issue=6&rft.spage=623&rft.epage=630&rft.pages=623-630&rft.issn=1755-375X&rft.eissn=1755-3768&rft_id=info:doi/10.1111/j.1755-3768.2009.01580.x&rft_dat=%3Cproquest_cross%3E67631029%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67631029&rft_id=info:pmid/19678810&rfr_iscdi=true |